Grufity logoGrufity logo

MRK

110.04USD+0.24(+0.22%)Market Closed

Merck & Co Inc

Market Summary

USD110.04+0.24Market Closed
0.22%

MRK Alerts

MRK Stock Price

RSI Chart

Valuation

Market Cap

255.3B

Price/Earnings

15.4

Price/Sales

4.47

Price/Cashflow

13.47

MarketCap/EBT

13.78

Price/Sales

Profitability

EBT Margin

32.40%

Return on Equity

38.34%

Return on Assets

15.48%

Fundamentals

Revenue

Revenue (TTM)

57.2B

Revenue Y/Y

27.99%

Revenue Q/Q

-8.23%

Earnings

Earnings (TTM)

16.6B

Earnings Y/Y

155.28%

Earnings Q/Q

-8.49%

Price Action

52 Week Range

69.08110.98
(Low)(High)

Last 7 days

2.4%

Last 30 days

10.7%

Last 90 days

28.6%

Trailing 12 Months

54.2%

Financial Health

Current Ratio

1.39

Investor Care

Dividend Yield

2.7%

Dividend/Share (TTM)

2.72

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

6.53

Peers (Alternatives to Merck)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
9.62% 31.13%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-11.83% -51.92%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Merck

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue5.9%57,16953,97848,70442,67542,072
  S&GA Expenses2.4%10,0019,7709,63410,33510,449
  R&D Expenses-12.3%10,88712,41012,24515,01915,923
Earnings Before Taxes17.6%18,52315,75313,87910,8288,268
Net Income16.9%16,57914,18013,0497,1975,571
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets0.4%107,095106,668105,69493,49490,688
  Current Assets3.0%32,11631,18430,26631,05828,665
    Cash Equivalents13.1%9,6758,5568,09610,0168,575
  Inventory-4.1%5,5355,7745,9535,6035,499
  Net PPE1.6%20,05919,74719,27918,56518,064
  Goodwill-0.2%21,21321,25821,26418,86218,873
  Current Liabilities3.8%23,16822,31623,87223,72821,906
    LT Debt, Current-2,300----
    LT Debt, Non Current-6.2%28,68430,58630,69022,90724,033
Shareholder's Equity5.8%43,24340,88338,18435,79433,294
  Retained Earnings3.9%58,43756,25253,69651,69148,777
  Additional Paid-In Capital-0.4%44,11544,27544,23844,14944,039
Accumulated Depreciation-3.8%17,79818,49818,19218,15518,236
Minority Interest7.1%7570736994
Float-196,870----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations17.8%18,95516,09213,12212,0339,409
  Share Based Compensation2.9%493479479481490
Cashflow From Investing8.9%-15,360.00-16,856.00-16,421.00-9,150.00-10,244.00
Cashflow From Financing-191.5%-1,930.002,1093,097-738.00-2,315.00
  Dividend Payments1.4%6,8076,7106,6106,5096,405
  Buy Backs43.1%1,202840822239

Risks

What is the probability of a big loss on MRK?

16.5%


Probability that Merck stock will be more than 20% underwater in next one year

0%


Probability that Merck stock will be more than 30% underwater in next one year.

0%


Probability that Merck stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does MRK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Merck was unfortunately bought at previous high price.

Returns

Cumulative Returns on MRK

13.6%


10-Year Cumulative Returns

15.1%


7-Year Cumulative Returns

19.3%


5-Year Cumulative Returns

13.3%


3-Year Cumulative Returns

What are the long-term rolling returns for MRK?

FIve years rolling returns for Merck.

Which funds bought or sold MRK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
SALEM CAPITAL MANAGEMENT INC
ADDED
0.16
-401,000
7,039,000
5.57%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-1.01
-23,916
354,000
0.22%
2022-11-23
Gould Capital, LLC
REDUCED
-0.69
-210,000
3,191,000
2.76%
2022-11-23
Toroso Investments, LLC
ADDED
8.57
285,000
11,445,000
0.48%
2022-11-22
Gibson Wealth Advisors LLC
ADDED
24.22
127,000
861,000
0.99%
2022-11-22
SMITH CHAS P & ASSOCIATES PA CPAS
ADDED
1.36
-1,387,000
31,236,000
2.65%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
714,000
714,000
0.03%
2022-11-22
IHT Wealth Management, LLC
ADDED
59.7
667,000
1,979,000
0.15%
2022-11-22
MFA Wealth Advisors, LLC
SOLD OFF
-100
-201,000
-
-%
2022-11-22
CVA Family Office, LLC
ADDED
27.5
146,000
858,000
0.23%

1–10 of 47

Latest Funds Activity

Are funds buying MRK calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own MRK

Merck News

Barron's

McCormick, PulteGroup, and Merck Boost Dividends.25 hours ago

MRK Fair Value

Recent SEC filings of Merck

View All Filings
Date Filed Form Type Document
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 07, 2022
4
Insider Trading
Nov 07, 2022
4
Insider Trading
Nov 03, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 01, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading

Latest Insider Trading transactions for MRK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-10
MIZELL STEVEN
SOLD
-1,521,280
101.419
-15,000
EVP, Chief HR Officer
2022-11-10
MIZELL STEVEN
ACQUIRED
-
-
15,000
EVP, Chief HR Officer
2022-11-09
Davis Robert M
SOLD
-17,169,800
102.437
-167,613
CEO & President
2022-11-09
Oosthuizen Johannes Jacobus
SOLD
-185,262
103.21
-1,795
President, U.S. Market
2022-11-09
Davis Robert M
ACQUIRED
-
-
167,613
CEO & President
2022-11-08
MIZELL STEVEN
ACQUIRED
-
-
20,000
EVP, Chief HR Officer
2022-11-08
MIZELL STEVEN
SOLD
-2,020,000
101
-20,000
EVP, Chief HR Officer
2022-11-07
Oosthuizen Johannes Jacobus
ACQUIRED
-
-
52,743
President, U.S. Market
2022-11-07
FRAZIER KENNETH C
ACQUIRED
-
-
235,769
Executive Chair
2022-11-07
Oosthuizen Johannes Jacobus
SOLD
-4,531,980
99.4706
-45,561
President, U.S. Market

1–10 of 50

MRK Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Sales$ 14,959$ 13,154$ 45,453$ 35,183
Costs, Expenses and Other    
Cost of sales3,9343,45013,5309,752
Selling, general and administrative2,5202,3367,3556,804
Research and development4,3992,4459,7739,177
Restructuring costs94107288487
Other (income) expense, net429(450)1,576(1,007)
Total Costs, Expenses and Other11,3767,88832,52225,213
Income from Continuing Operations Before Taxes3,5835,26612,9319,970
Taxes on Income from Continuing Operations3306951,4231,436
Net Income from Continuing Operations3,2534,57111,5088,534
Less: Net Income Attributable to Noncontrolling Interests5469
Net Income from Continuing Operations Attributable to Merck & Co., Inc.3,2484,56711,5028,525
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests000766
Net Income Attributable to Merck & Co., Inc.$ 3,248$ 4,567$ 11,502$ 9,291
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:    
Income from Continuing Operations (in dollars per share)$ 1.28$ 1.81$ 4.55$ 3.37
Income from Discontinued Operations (in dollars per share)0000.30
Net Income (in dollars per share)1.281.814.553.67
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:    
Income from Continuing Operations (in dollars per share)1.281.804.533.36
Income from Discontinued Operations (in dollars per share)0000.30
Net Income (in dollars per share)$ 1.28$ 1.80$ 4.53$ 3.66

MRK Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets  
Cash and cash equivalents$ 11,145$ 8,096
Short-term investments1030
Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021)9,4829,230
Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7)5,6145,953
Other current assets7,2176,987
Total current assets33,56130,266
Investments984370
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 202120,42419,279
Goodwill21,16021,264
Other Intangibles, Net21,36822,933
Other Assets9,58411,582
Total Assets107,081105,694
Current Liabilities  
Loans payable and current portion of long-term debt1,9362,412
Trade accounts payable3,3714,609
Accrued and other current liabilities14,22213,859
Income taxes payable1,6981,224
Dividends payable1,7711,768
Total current liabilities22,99823,872
Long-Term Debt28,48230,690
Deferred Income Taxes2,4173,441
Other Noncurrent Liabilities8,6609,434
Merck & Co., Inc. Stockholders’ Equity  
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 20211,7881,788
Other paid-in capital44,24344,238
Retained earnings59,92853,696
Accumulated other comprehensive loss(4,743)(4,429)
Stockholders' equity before deduction for treasury stock101,21695,293
Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 202156,75857,109
Total Merck & Co., Inc. stockholders’ equity44,45838,184
Noncontrolling Interests6673
Total equity44,52438,257
Liabilities and Equity$ 107,081$ 105,694